<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2E0C7934-84C6-4D75-8BE2-3290AAA93F3D"><gtr:id>2E0C7934-84C6-4D75-8BE2-3290AAA93F3D</gtr:id><gtr:name>Assistance Publique ? H?pitaux de Paris</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/30205A78-AF40-4601-B72C-8CF769C1D346"><gtr:id>30205A78-AF40-4601-B72C-8CF769C1D346</gtr:id><gtr:name>University Hospital Jena</gtr:name><gtr:address><gtr:line1>Bachstrasse 18</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E2D70FF9-F1CF-4841-95BA-71F3959764AD"><gtr:id>E2D70FF9-F1CF-4841-95BA-71F3959764AD</gtr:id><gtr:name>Medical University of Warsaw</gtr:name><gtr:address><gtr:line1>Zwirki i Wigury 67</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B85C9507-1FE0-420C-BAC8-8DC91772F172"><gtr:id>B85C9507-1FE0-420C-BAC8-8DC91772F172</gtr:id><gtr:name>Kantonsspital St. Gallen</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/22FC5EB4-C5EC-4751-9C2E-7F03B1DC354B"><gtr:id>22FC5EB4-C5EC-4751-9C2E-7F03B1DC354B</gtr:id><gtr:name>University of Ulm</gtr:name><gtr:address><gtr:line1>Albert Einstein Allee 5</gtr:line1><gtr:line4>Ulm</gtr:line4><gtr:postCode>89081</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2718B5D3-B880-4C4C-A4A3-0E639BDA800E"><gtr:id>2718B5D3-B880-4C4C-A4A3-0E639BDA800E</gtr:id><gtr:name>BMI The Beaumont Hospital</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:department>Neurosciences</gtr:department><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2E0C7934-84C6-4D75-8BE2-3290AAA93F3D"><gtr:id>2E0C7934-84C6-4D75-8BE2-3290AAA93F3D</gtr:id><gtr:name>Assistance Publique ? H?pitaux de Paris</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/30205A78-AF40-4601-B72C-8CF769C1D346"><gtr:id>30205A78-AF40-4601-B72C-8CF769C1D346</gtr:id><gtr:name>University Hospital Jena</gtr:name><gtr:address><gtr:line1>Bachstrasse 18</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E2D70FF9-F1CF-4841-95BA-71F3959764AD"><gtr:id>E2D70FF9-F1CF-4841-95BA-71F3959764AD</gtr:id><gtr:name>Medical University of Warsaw</gtr:name><gtr:address><gtr:line1>Zwirki i Wigury 67</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B85C9507-1FE0-420C-BAC8-8DC91772F172"><gtr:id>B85C9507-1FE0-420C-BAC8-8DC91772F172</gtr:id><gtr:name>Kantonsspital St. Gallen</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/22FC5EB4-C5EC-4751-9C2E-7F03B1DC354B"><gtr:id>22FC5EB4-C5EC-4751-9C2E-7F03B1DC354B</gtr:id><gtr:name>University of Ulm</gtr:name><gtr:address><gtr:line1>Albert Einstein Allee 5</gtr:line1><gtr:line4>Ulm</gtr:line4><gtr:postCode>89081</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2718B5D3-B880-4C4C-A4A3-0E639BDA800E"><gtr:id>2718B5D3-B880-4C4C-A4A3-0E639BDA800E</gtr:id><gtr:name>BMI The Beaumont Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E3406FFA-68B6-49BB-A34C-5A9008DA9B5A"><gtr:id>E3406FFA-68B6-49BB-A34C-5A9008DA9B5A</gtr:id><gtr:firstName>Pamela</gtr:firstName><gtr:otherNames>Jean</gtr:otherNames><gtr:surname>Shaw</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4BEC98FE-2732-40D3-9710-DF55EB45D3C3"><gtr:id>4BEC98FE-2732-40D3-9710-DF55EB45D3C3</gtr:id><gtr:firstName>Janine</gtr:firstName><gtr:surname>Kirby</gtr:surname><gtr:orcidId>0000-0002-7468-5917</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK000039%2F1"><gtr:id>DADB4069-823C-48FC-927A-E8DE5536DD67</gtr:id><gtr:title>Sampling and biomarker OPtimisation and Harmonisation In ALS and other motor neuron diseases (SOPHIA)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/K000039/1</gtr:grantReference><gtr:abstractText>Amyotrophic Lateral Sclerosis (ALS) is one of the most devastating diseases in neurology affecting some 50,000 individuals at any time in Europe, and causing around 10,000 deaths each year. The main clinical features are weakness and wasting of muscles, but dementia may also occur. ALS represents a good model for study of all neurodegenerative conditions, as it has a characteristic phenotype, rapid progression and the correlation between diagnosis during life and autopsy diagnosis is close to 100%. However, validated neurochemical biomarkers for monitoring disease activity, for generating earlier diagnoses and for defining prognosis are lacking. Active European collaborations are in place for harmonizing clinical datasets, neuroimaging and neuropathology protocols. A preliminary strategy for harmonization of biological and tissue samples has been established. Standardized protocols for clinical data and sample collection are now urgently required for optimization and harmonization of biomarker development. 
The overall aim of this proposal is to provide a common European strategy for the prioritization and selection of candidate biomarker domains for optimization and harmonization. This will in turn provide a long-term platform by which existing collaborative structures that are relevant to neurodegenerative disease biomarkers (including academic initiatives, co-funding strategies, biobanks, industrial efforts, private-public alliances) are integrated within an inclusive web-based virtual biobank. Samples and clinical/imaging/neurophysiologic and neuropathological datasets provided by participating members can then be optimally utilized to enable state of the art collaborative analyses.
The established platform will also act as an important communication channel between this consortium and the rest of the ALS/Neurodegeneration field to ensure that the optimization efforts are in line with the whole ALS/ND field, to avoid duplication of work, and to ensure better acceptance and utilization of the project results by all stakeholders. Ultimately, the platform will be used to disseminate the results to the whole ALS/Neurodegeneration field, and will act as a permanent Interactive European ALS biomarker platform for researchers to optimize/harmonize novel biomarkers using an established pan-European ALS methodology. The platform will also allow interaction with those of other cognate groups (e.g the NEALS group within the US) and with patient groups and other relevant stakeholders.</gtr:abstractText><gtr:technicalSummary>Amyotrophic Lateral Sclerosis (ALS) is one of the most devastating diseases in neurology affecting some 50,000 individuals at any time in Europe, and causing around 10.000 deaths each year. The motor system (upper motor neurons in the motor cortex and lower motor neurons in the spinal cord) is preferentially affected. Whilst correlation between clinical and autopsy diagnosis is close to 100%, validated neurochemical biomarkers for monitoring disease activity, earlier diagnosis and defining prognosis are lacking. Thus, standardized protocols for clinical data and sample collection are now urgently required for optimization and harmonization of biomarker development.
The overall aim of this proposal is to provide a common European strategy for the prioritization and selection of candidate biomarker domains for optimization and harmonization. This will in turn provide a long term platform by which existing collaborative structures that are relevant to neurodegenerative disease biomarkers (including academic initiatives, co-funding strategies, biobanks, industrial efforts, private-public alliances) are integrated within an inclusive web-based virtual biobank. Samples and clinical, imaging, neurophysiologic and neuropathological datasets provided by participating members can then be optimally utilized to enable state of the art collaborative analyses. The established platform will act as an important communication channel between this consortium and the broader international ALS/Neurodegeneration field, to ensure that the optimization efforts are consistently applied. Ultimately, the platform will establish a permanent Interactive European ALS biomarker tool for all researchers, and will enable ongoing optimization/harmonization of novel biomarkers using an integrated and robust pan-European ALS methodology. The platform will allow interaction with those of other cognate groups (e.g the NEALS group within the US), with patient groups and other relevant stakeholders.</gtr:technicalSummary><gtr:potentialImpactText>ALS is one of the most devastating neurodegenerative diseases for which no therapy exist. As such, the existence of a set of optimized and standardized methods for collection, preservation and analysis of different biomarkers necessary to evaluate diagnosis and disease progression of ALS and other motor neuron diseases will be an enormous advance in the investigation of this condition at several levels, possibly transferable to other forms of neurodegeneration. 

The impact would involve many different areas:

1- Systematic multicentre investigation to permit an earlier and more reliable diagnosis has two major implications:
a. Less time consuming expensive investigations before reaching the final diagnosis of ALS, avoiding unnecessary interventions such as surgical procedures 
b. Earlier clinical trial entry with high chances of defining an effective drug
2- All methods, database, biomarker essays, and biomarker in SOPHIA will be shared with other members of the scientific community devoted to ALS and to other ND.
3- The concept of this project (pan-European SOPs) can be expanded to other ND resulting in a driving force for shared biomarker research.
4- Better understanding of ALS etiopathogenesis and natural history.
5- The project will increase the interest of the international scientific community in relation to ALS.
6- Identification of consistent biomarker in ALS will permit less expensive, smaller, and shorter trials with better stratified early ALS patients, with increased probability to find an effective drug. 
7- Availability of more precise measures of disease activity and disease progression will improve trial design and thereby attract pharmaceutical industry to investigate new compounds in ALS.
8- Improved patient care as a systematic questionnaire is applied to permit a proper evaluation. A potential biomarker will allow a more scientific evaluation of all interventions.
9- Patients association satisfied with higher care quality: all interventions will be more appropriately measured due to this project.
10- The finding of potential biomarker(s) will allow the development of new European commercial opportunities to develop biomarker detection kits for use in neurodegeneration clinical practice. 
11- The project will demonstrate the impact of a large European multicentric project in relation to a relatively rare disorder acting as a template for other conditions in the future.
12- SOPHIA will for the first time establish an Interactive European ALS biomarker website, that serves as a vehicle to support implementation of the pan-European methodology on ALS biomarker optimization and harmonization. This platform engages with end-users in an early stage, thereby improving acceptation and implementation of project results by these stakeholders. Possibilities for co-funding and member fees will be examined to ensure that this platform will be sustainable. When successful, this platform can be extended to / implemented in other ND areas.</gtr:potentialImpactText><gtr:fund><gtr:end>2015-11-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>141215</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Assistance Publique ? H?pitaux de Paris</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Department of Neuropathology</gtr:department><gtr:description>Neuropathology Consortium</gtr:description><gtr:id>7FCBA1AB-6967-4782-8D4D-3CEEC3884810</gtr:id><gtr:impact>Draft documents prepared and agreed.
Database being prepared for input of data.</gtr:impact><gtr:outcomeId>H2S2AH2o9dt-2</gtr:outcomeId><gtr:partnerContribution>Other partners have contributed to our centres proposals (as we are leading on this collaboration)</gtr:partnerContribution><gtr:piContribution>Collaboration between the Neuropathologists at each centre to devise a harmonised protocol for collection, handling and storage of post-mortem ALS cases. This is due to be accompanied with key data which will be submitted in an anonymised fashion on a database in order to establish a virtual brain tissue bank across Europe.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Kantonsspital St. Gallen</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>Department of Neuropathology</gtr:department><gtr:description>Neuropathology Consortium</gtr:description><gtr:id>75B3370A-A898-450C-8AE4-9D91151CB76C</gtr:id><gtr:impact>Draft documents prepared and agreed.
Database being prepared for input of data.</gtr:impact><gtr:outcomeId>H2S2AH2o9dt-7</gtr:outcomeId><gtr:partnerContribution>Other partners have contributed to our centres proposals (as we are leading on this collaboration)</gtr:partnerContribution><gtr:piContribution>Collaboration between the Neuropathologists at each centre to devise a harmonised protocol for collection, handling and storage of post-mortem ALS cases. This is due to be accompanied with key data which will be submitted in an anonymised fashion on a database in order to establish a virtual brain tissue bank across Europe.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Ulm</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Laboratory of Neuropathology</gtr:department><gtr:description>Neuropathology Consortium</gtr:description><gtr:id>152FE44A-8FF7-419E-BDC7-D26AD5A02B14</gtr:id><gtr:impact>Draft documents prepared and agreed.
Database being prepared for input of data.</gtr:impact><gtr:outcomeId>H2S2AH2o9dt-3</gtr:outcomeId><gtr:partnerContribution>Other partners have contributed to our centres proposals (as we are leading on this collaboration)</gtr:partnerContribution><gtr:piContribution>Collaboration between the Neuropathologists at each centre to devise a harmonised protocol for collection, handling and storage of post-mortem ALS cases. This is due to be accompanied with key data which will be submitted in an anonymised fashion on a database in order to establish a virtual brain tissue bank across Europe.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital Jena</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Department of Neuropathology</gtr:department><gtr:description>Neuropathology Consortium</gtr:description><gtr:id>4A8B1BD7-0AA9-41D2-8A5E-6F4BDAACEE19</gtr:id><gtr:impact>Draft documents prepared and agreed.
Database being prepared for input of data.</gtr:impact><gtr:outcomeId>H2S2AH2o9dt-4</gtr:outcomeId><gtr:partnerContribution>Other partners have contributed to our centres proposals (as we are leading on this collaboration)</gtr:partnerContribution><gtr:piContribution>Collaboration between the Neuropathologists at each centre to devise a harmonised protocol for collection, handling and storage of post-mortem ALS cases. This is due to be accompanied with key data which will be submitted in an anonymised fashion on a database in order to establish a virtual brain tissue bank across Europe.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical University of Warsaw</gtr:collaboratingOrganisation><gtr:country>Poland, Republic of</gtr:country><gtr:department>Department of Neuropathology</gtr:department><gtr:description>Neuropathology Consortium</gtr:description><gtr:id>2674E64A-E187-4D26-B833-28CCF117982D</gtr:id><gtr:impact>Draft documents prepared and agreed.
Database being prepared for input of data.</gtr:impact><gtr:outcomeId>H2S2AH2o9dt-6</gtr:outcomeId><gtr:partnerContribution>Other partners have contributed to our centres proposals (as we are leading on this collaboration)</gtr:partnerContribution><gtr:piContribution>Collaboration between the Neuropathologists at each centre to devise a harmonised protocol for collection, handling and storage of post-mortem ALS cases. This is due to be accompanied with key data which will be submitted in an anonymised fashion on a database in order to establish a virtual brain tissue bank across Europe.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>BMI The Beaumont Hospital</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:department>Neuropathology</gtr:department><gtr:description>Neuropathology Consortium</gtr:description><gtr:id>A2924609-7278-461A-9216-0CD34C843185</gtr:id><gtr:impact>Draft documents prepared and agreed.
Database being prepared for input of data.</gtr:impact><gtr:outcomeId>H2S2AH2o9dt-5</gtr:outcomeId><gtr:partnerContribution>Other partners have contributed to our centres proposals (as we are leading on this collaboration)</gtr:partnerContribution><gtr:piContribution>Collaboration between the Neuropathologists at each centre to devise a harmonised protocol for collection, handling and storage of post-mortem ALS cases. This is due to be accompanied with key data which will be submitted in an anonymised fashion on a database in order to establish a virtual brain tissue bank across Europe.</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Sir William Dunn School of Pathology</gtr:department><gtr:description>Neuropathology Consortium</gtr:description><gtr:id>E2A15A0F-29C2-48B1-BD22-CE55B6BE0C98</gtr:id><gtr:impact>Draft documents prepared and agreed.
Database being prepared for input of data.</gtr:impact><gtr:outcomeId>H2S2AH2o9dt-1</gtr:outcomeId><gtr:partnerContribution>Other partners have contributed to our centres proposals (as we are leading on this collaboration)</gtr:partnerContribution><gtr:piContribution>Collaboration between the Neuropathologists at each centre to devise a harmonised protocol for collection, handling and storage of post-mortem ALS cases. This is due to be accompanied with key data which will be submitted in an anonymised fashion on a database in order to establish a virtual brain tissue bank across Europe.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>2576509</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>A multicentre biomarker resource strategy in ALS: AMBRoSIA.</gtr:description><gtr:end>2020-07-02</gtr:end><gtr:fundingOrg>Motor Neurone Disease Association (MND)</gtr:fundingOrg><gtr:id>CF591172-D68B-4745-91B9-A4911F0C303E</gtr:id><gtr:outcomeId>56f32879d90401.85022462</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4049681</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre</gtr:department><gtr:description>NIHR Biomedical Research Centre: Translational Neuroscience for Chronic Neurological Disorders</gtr:description><gtr:end>2022-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>6C213DB1-EBCA-473E-90FB-AF85C9FA95C2</gtr:id><gtr:outcomeId>58c9a5e9f2b758.33619734</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>105185</gtr:amountPounds><gtr:country>Saudi Arabia, Kingdom of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>The generation and characterisation of stem-cell derived astrocytes, from skin biopsies of genetic subgroups of motor neuron disease.</gtr:description><gtr:end>2016-07-02</gtr:end><gtr:fundingOrg>Government of Saudi Arabia</gtr:fundingOrg><gtr:id>380B77E1-156D-4BC3-A87F-7EB5C5538E26</gtr:id><gtr:outcomeId>56f326b11291b4.90420518</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>5980436</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MIROCALS (modifying immune response and outcomes in ALS). Efficacy and safety of low-dose IL-2 (Id-IL-2) as a Treg enhancer for anti-inflammatory therapy in newly diagnosed amyotrophic lateral sclerosis (ALS) patients.</gtr:description><gtr:end>2018-05-02</gtr:end><gtr:fundingOrg>European Economic Community</gtr:fundingOrg><gtr:id>02996BC4-CA69-418F-A6FB-989F53887006</gtr:id><gtr:outcomeId>56f325c83a5775.19155124</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>247954</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>2015-2018 &amp;pound;247,954. Bioenergetic profiling of cellular ALS models (MNDA Senior Non-Clinical Fellowship - Scott Allen, Allen/Oct15/956-799).</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Motor Neurone Disease Association (MND)</gtr:fundingOrg><gtr:fundingRef>Allen/Oct15/956-799</gtr:fundingRef><gtr:id>5CE2B5B0-C368-45B0-A98D-AE1F2B756D85</gtr:id><gtr:outcomeId>58c9a53cf2b4c6.07225540</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Cerebrospinal fluid from ALS cases and controls was sent to Markus Otto at Ulm University, Germany to perform measurement of specific biomarkers associated with ALS. This work demonstrated the variability in samples between European centres, due to sample collection, handling and storage.</gtr:description><gtr:id>CC440695-3D27-4020-8AD2-04062B66750F</gtr:id><gtr:impact>Publication submitted to &amp;quot;Amyotrophic lateral sclerosis and frontotemporal degeneration&amp;quot;</gtr:impact><gtr:outcomeId>apnBowCMy8L</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Cerebrospinal fluid biosamples to Dr Markus Otto in Ulm</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Standardised method for collecting data from patient MRI scans applicable to multi-centre studies.</gtr:description><gtr:id>137508DE-61DE-410A-B3F3-CC015BE2723F</gtr:id><gtr:impact>Will facilitate multicentre biomarker analysis of imaging parameters.</gtr:impact><gtr:outcomeId>56dd87727bd329.46685931</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Contributed to multi-centre assessment of imaging biomarkers of disease progression in ALS/MND.</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A method for quantifying motor neuron numbers over the disease course.</gtr:description><gtr:id>42BA38DA-3E5D-48AC-99CA-0923399DD00E</gtr:id><gtr:impact>A quantitative tool for assessment of motor neuron numbers which can be used in multi centre studies over the disease course.</gtr:impact><gtr:outcomeId>56dd86bfbd2444.96880721</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Development of MUNIX for neurophysiological assessment of MND patients.</gtr:title><gtr:type>Physiological assessment or outcome measure</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>01B3AA83-D56E-43D7-AA74-4BCFC87B3AFE</gtr:id><gtr:title>Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6883810a16e61c37ff340736f6cdf792"><gtr:id>6883810a16e61c37ff340736f6cdf792</gtr:id><gtr:otherNames>van Rheenen W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>58c6add88c4496.09700924</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D28EB610-FBDB-4E9B-BC9F-5121B96B9842</gtr:id><gtr:title>Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9fa71eb5bcb5dbba5a77cb5d30c89ec3"><gtr:id>9fa71eb5bcb5dbba5a77cb5d30c89ec3</gtr:id><gtr:otherNames>Oeckl P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>58c7d40fc834f1.53803890</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47598A3E-A482-495F-A559-00B8C81DE8EE</gtr:id><gtr:title>Case report of concurrent Fabry disease and amyotrophic lateral sclerosis supports a common pathway of pathogenesis.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8be76b4be2b2f7cd39c6b62a634ab40b"><gtr:id>8be76b4be2b2f7cd39c6b62a634ab40b</gtr:id><gtr:otherNames>Beer AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>58c7e729604362.35199086</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DDC10529-4A42-4CC0-82A9-7CFC552F2ABA</gtr:id><gtr:title>The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5bb0f592e8014472d5082208157baad"><gtr:id>c5bb0f592e8014472d5082208157baad</gtr:id><gtr:otherNames>Cooper-Knock J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>5461e702bec1e5.62250336</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6D27FA0-C48E-4128-96CA-B2D3A97F4410</gtr:id><gtr:title>Long-term physical activity: an exogenous risk factor for sporadic amyotrophic lateral sclerosis?</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb45c2d93a5b6d33434a0ec6929f0077"><gtr:id>bb45c2d93a5b6d33434a0ec6929f0077</gtr:id><gtr:otherNames>Harwood CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>56f2a8f31da285.59188615</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3AB9514-374C-4F02-89C1-61FCBD984069</gtr:id><gtr:title>C9ORF72 transcription in a frontotemporal dementia case with two expanded alleles.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5bb0f592e8014472d5082208157baad"><gtr:id>c5bb0f592e8014472d5082208157baad</gtr:id><gtr:otherNames>Cooper-Knock J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_23953_23_24107864</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6632120-AC61-4619-AA54-70B9F1074906</gtr:id><gtr:title>Motor neurone disease/amyotrophic lateral sclerosis associated with intermediate-length CAG repeat expansions in Ataxin-2 does not have 1C2-positive polyglutamine inclusions.</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/035fd6446ad51dcfd45eac40f171f90d"><gtr:id>035fd6446ad51dcfd45eac40f171f90d</gtr:id><gtr:otherNames>Highley JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn><gtr:outcomeId>56dd8508d6f133.40961569</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60BB6A47-B28A-4E60-A369-7BCCB5571865</gtr:id><gtr:title>C9ORF72 expansions, parkinsonism, and Parkinson disease: a clinicopathologic study.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5bb0f592e8014472d5082208157baad"><gtr:id>c5bb0f592e8014472d5082208157baad</gtr:id><gtr:otherNames>Cooper-Knock J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>pm_23953_23_23884045</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B39FF354-0AB1-4BF0-9402-FFFA1F344703</gtr:id><gtr:title>The Spectrum of C9orf72-mediated Neurodegeneration and Amyotrophic Lateral Sclerosis.</gtr:title><gtr:parentPublicationTitle>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5bb0f592e8014472d5082208157baad"><gtr:id>c5bb0f592e8014472d5082208157baad</gtr:id><gtr:otherNames>Cooper-Knock J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1878-7479</gtr:issn><gtr:outcomeId>56f29ceb7bf814.57259102</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D39DC216-0769-4081-A728-ACCFFEE07C1C</gtr:id><gtr:title>Intermediate length C9orf72 expansion in an ALS patient without classical C9orf72 neuropathology.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8be76b4be2b2f7cd39c6b62a634ab40b"><gtr:id>8be76b4be2b2f7cd39c6b62a634ab40b</gtr:id><gtr:otherNames>Beer AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>548a1a5f9d33c8.11603266</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A25051E-56B4-4FC0-95DE-048FF65968A9</gtr:id><gtr:title>Loss of nuclear TDP-43 in amyotrophic lateral sclerosis (ALS) causes altered expression of splicing machinery and widespread dysregulation of RNA splicing in motor neurones.</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/035fd6446ad51dcfd45eac40f171f90d"><gtr:id>035fd6446ad51dcfd45eac40f171f90d</gtr:id><gtr:otherNames>Highley JR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn><gtr:outcomeId>5461e70323f625.14844392</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0DAF26A-226A-4B2C-B492-8358AD370FCD</gtr:id><gtr:title>Invited review: decoding the pathophysiological mechanisms that underlie RNA dysregulation in neurodegenerative disorders: a review of the current state of the art.</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d7a2d9405adbdec6ffa1d89cdb95f6a8"><gtr:id>d7a2d9405adbdec6ffa1d89cdb95f6a8</gtr:id><gtr:otherNames>Walsh MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn><gtr:outcomeId>5461e70349e870.83431899</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9F0B2FE5-D532-43EA-877B-ABE741178D30</gtr:id><gtr:title>Gene expression signatures in motor neurone disease fibroblasts reveal dysregulation of metabolism, hypoxia-response and RNA processing functions.</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ebf33d15f299bb3b0fef70ac74f5deb7"><gtr:id>ebf33d15f299bb3b0fef70ac74f5deb7</gtr:id><gtr:otherNames>Raman R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn><gtr:outcomeId>5461e66493ca23.98249457</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4256657A-E377-4A82-835E-6F903CF8C376</gtr:id><gtr:title>Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2dfac3c0b078a8f58445af96f7a94315"><gtr:id>2dfac3c0b078a8f58445af96f7a94315</gtr:id><gtr:otherNames>Lehnert S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>5461e702e4b6b9.35723890</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53194B7F-FF16-4434-9E91-D76DB780B63D</gtr:id><gtr:title>Small RNA Sequencing of Sporadic Amyotrophic Lateral Sclerosis Cerebrospinal Fluid Reveals Differentially Expressed miRNAs Related to Neural and Glial Activity.</gtr:title><gtr:parentPublicationTitle>Frontiers in neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66079fb1368a21e3c96fbfc6c67c9009"><gtr:id>66079fb1368a21e3c96fbfc6c67c9009</gtr:id><gtr:otherNames>Waller R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1662-453X</gtr:issn><gtr:outcomeId>5a67bc03bb8213.59585922</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26324863-3AFD-44D2-B22C-A5FDCF5F51D5</gtr:id><gtr:title>Creatine kinase enzyme level correlates positively with serum creatinine and lean body mass, and is a prognostic factor for survival in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>European journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c79666fcb0b64cd022706f2f1cba129e"><gtr:id>c79666fcb0b64cd022706f2f1cba129e</gtr:id><gtr:otherNames>Rafiq MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1351-5101</gtr:issn><gtr:outcomeId>58c7d339204cf1.83490885</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>507821A0-9296-473E-8A29-8A0F08A4CFC8</gtr:id><gtr:title>TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/097fa5ac687e318ffb9ff4b6418aefdc"><gtr:id>097fa5ac687e318ffb9ff4b6418aefdc</gtr:id><gtr:otherNames>Gallagher MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>5462087e529223.40149410</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C94186B5-57F9-459A-9C2D-9A50718C2124</gtr:id><gtr:title>NEK1 variants confer susceptibility to amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Nature genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa8dc20d96363a2f4e574a132c76feaf"><gtr:id>aa8dc20d96363a2f4e574a132c76feaf</gtr:id><gtr:otherNames>Kenna KP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1061-4036</gtr:issn><gtr:outcomeId>58c7e9147e2be3.35089119</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>86320A50-B5CA-4FA8-A9A5-2BC8EADE4E1F</gtr:id><gtr:title>Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5bb0f592e8014472d5082208157baad"><gtr:id>c5bb0f592e8014472d5082208157baad</gtr:id><gtr:otherNames>Cooper-Knock J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>54620834dd9a57.08110631</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D9621F7-3571-44E5-9869-5C29B0B7E89A</gtr:id><gtr:title>Neuronal dark matter: the emerging role of microRNAs in neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Frontiers in cellular neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdc5a5c7ae7d76540805ecf9c81c4850"><gtr:id>cdc5a5c7ae7d76540805ecf9c81c4850</gtr:id><gtr:otherNames>Goodall EF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1662-5102</gtr:issn><gtr:outcomeId>pm_23953_23_24133413</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>19859186-4651-4502-A469-0B56D10F34ED</gtr:id><gtr:title>Investigating cell death mechanisms in amyotrophic lateral sclerosis using transcriptomics.</gtr:title><gtr:parentPublicationTitle>Frontiers in cellular neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/64df6fe9889ada20f846e8d9f3305c53"><gtr:id>64df6fe9889ada20f846e8d9f3305c53</gtr:id><gtr:otherNames>Heath PR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1662-5102</gtr:issn><gtr:outcomeId>546208cd698431.50905799</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CFDBC00-DF01-47B6-811E-27C6861D9C50</gtr:id><gtr:title>C9ORF72 GGGGCC Expanded Repeats Produce Splicing Dysregulation which Correlates with Disease Severity in Amyotrophic Lateral Sclerosis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5bb0f592e8014472d5082208157baad"><gtr:id>c5bb0f592e8014472d5082208157baad</gtr:id><gtr:otherNames>Cooper-Knock J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56f29e8ba44391.37734418</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>009FB0C3-04BA-48B1-908F-FF60B7BCFFD1</gtr:id><gtr:title>Antisense RNA foci in the motor neurons of C9ORF72-ALS patients are associated with TDP-43 proteinopathy.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5bb0f592e8014472d5082208157baad"><gtr:id>c5bb0f592e8014472d5082208157baad</gtr:id><gtr:otherNames>Cooper-Knock J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn><gtr:outcomeId>56f29db61585b0.65969034</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66B24CB8-51E6-47FA-BD67-FD24BA5E8A4C</gtr:id><gtr:title>Comparison of the King's and MiToS staging systems for ALS.</gtr:title><gtr:parentPublicationTitle>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/65b06f62a28aa16278494b24ff99202a"><gtr:id>65b06f62a28aa16278494b24ff99202a</gtr:id><gtr:otherNames>Fang T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2167-8421</gtr:issn><gtr:outcomeId>58c65780bd7267.14001260</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>74B805AD-E8F2-44B2-B012-8F758CC27BE9</gtr:id><gtr:title>Lysosomal and phagocytic activity is increased in astrocytes during disease progression in the SOD1 (G93A) mouse model of amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>Frontiers in cellular neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/975397a544998ea3f6045022938ff775"><gtr:id>975397a544998ea3f6045022938ff775</gtr:id><gtr:otherNames>Baker DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1662-5102</gtr:issn><gtr:outcomeId>56f2ada331df34.47686472</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E5FC51C-F2D5-439B-A07F-835CE2E9B6B5</gtr:id><gtr:title>Oligogenic inheritance of optineurin (OPTN) and C9ORF72 mutations in ALS highlights localisation of OPTN in the TDP-43-negative inclusions of C9ORF72-ALS.</gtr:title><gtr:parentPublicationTitle>Neuropathology : official journal of the Japanese Society of Neuropathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b713041ea74e48ad43be6b3c33a3888"><gtr:id>7b713041ea74e48ad43be6b3c33a3888</gtr:id><gtr:otherNames>Bury JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0919-6544</gtr:issn><gtr:outcomeId>56dd85090a22d0.92782342</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B2F19D7-3D13-4342-A67C-46B8DDE2A4B8</gtr:id><gtr:title>The genetics of amyotrophic lateral sclerosis: current insights</gtr:title><gtr:parentPublicationTitle>Degenerative Neurological and Neuromuscular Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5b9bdf6846b8ebf535c64350b137b2b"><gtr:id>c5b9bdf6846b8ebf535c64350b137b2b</gtr:id><gtr:otherNames>Kirby J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58c9089e073785.54252143</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A404436-58F5-4C58-A893-BB70F2877593</gtr:id><gtr:title>Comparison of blood RNA extraction methods used for gene expression profiling in amyotrophic lateral sclerosis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1af15fffd81b453968ad48d3102ce6df"><gtr:id>1af15fffd81b453968ad48d3102ce6df</gtr:id><gtr:otherNames>Bayatti N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5461e70295c654.06780610</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81663D99-51AA-4D05-AB0D-01EA8816F191</gtr:id><gtr:title>Targeted Genetic Screen in Amyotrophic Lateral Sclerosis Reveals Novel Genetic Variants with Synergistic Effect on Clinical Phenotype.</gtr:title><gtr:parentPublicationTitle>Frontiers in molecular neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5bb0f592e8014472d5082208157baad"><gtr:id>c5bb0f592e8014472d5082208157baad</gtr:id><gtr:otherNames>Cooper-Knock J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1662-5099</gtr:issn><gtr:outcomeId>5aa001857f2f97.03169325</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D00D9734-0B24-4727-9C68-B3E62E5F69F9</gtr:id><gtr:title>Genetic correlation between amyotrophic lateral sclerosis and schizophrenia.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/150e9e10e3ebe78c54e55b675bce02c7"><gtr:id>150e9e10e3ebe78c54e55b675bce02c7</gtr:id><gtr:otherNames>McLaughlin RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5aa138695dfaa2.09380811</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K000039/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>5191BE6E-A234-4D62-A4F3-B50DBAAE8217</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.5  Resources and infrastructure (detection)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>